Experimental STING drug aims to rev up immune system against stubborn leukemia

NCT ID NCT06626633

Terminated Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called CRD3874-SI, which activates the STING protein to help the immune system attack cancer cells. It is for adults with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety and find the right dose. Only 6 participants are enrolled, and the study is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CRD3874-SI (a STING agonist drug that stimulates the immune system to fight cancer)
What this could lead to: If this works, it could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia by boosting the immune system to kill cancer cells.
What could go wrong: This is a very early Phase 1 trial with only 6 participants, so results are preliminary. The study is currently suspended, and it is unknown if the drug will be safe or effective in humans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

University of Maryland, Baltimore

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.